Myovant Sciences Current Ratio 2017-2021 | MYOV

Myovant Sciences current ratio from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Myovant Sciences Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-09-30 $0.66B $0.27B 2.44
2021-06-30 $0.70B $0.31B 2.28
2021-03-31 $0.71B $0.28B 2.51
2020-12-31 $0.75B $0.25B 2.99
2020-09-30 $0.12B $0.07B 1.75
2020-06-30 $0.11B $0.05B 2.07
2020-03-31 $0.09B $0.09B 1.02
2019-12-31 $0.11B $0.05B 2.08
2019-09-30 $0.17B $0.06B 2.79
2019-06-30 $0.24B $0.07B 3.42
2019-03-31 $0.17B $0.07B 2.32
2018-12-31 $0.20B $0.06B 3.51
2018-09-30 $0.16B $0.05B 3.41
2018-06-30 $0.15B $0.05B 3.07
2018-03-31 $0.12B $0.04B 3.10
2017-12-31 $0.14B $0.03B 5.04
2017-09-30 $0.13B $0.02B 7.79
2017-06-30 $0.16B $0.02B 9.27
2017-03-31 $0.18B $0.02B 10.04
2016-12-31 $0.19B $0.01B 30.53
2016-09-30 $0.00B $0.01B 0.02
2016-06-30 $0.00B $0.00B 0.00
2016-03-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.368B $0.059B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90